Syncom Formulations (India) Ltd

Syncom Formul. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syncom Formulations (India) Ltd

₹ 18.2 -0.22%
15 Jan 12:03 p.m.
syncomformulations.com BSE: 524470 NSE: SYNCOMF
About

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Key Points

Business Overview
The company manufactures and markets 500+ pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. It is also involved in trading commodities and rental of properties. [1]

Website BSE NSE
  • Market Cap ₹ 1,709 Cr.
  • Current Price ₹ 18.2
  • High / Low ₹ 27.9 / 11.0
  • Stock P/E 53.8
  • Book Value ₹ 3.32
  • Dividend Yield 0.00 %
  • ROCE 10.2 %
  • ROE 8.51 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Stock is trading at 5.50 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 6.60% over past five years.
  • Company has a low return on equity of 8.77% over last 3 years.
  • Earnings include an other income of Rs.13.7 Cr.
  • Dividend payout has been low at 4.36% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
53 57 58 51 54 57 61 59 62 63 73 86 101
47 52 56 48 50 51 55 53 56 57 64 76 90
Operating Profit 6 5 2 3 4 6 6 6 6 7 9 10 12
OPM % 11% 9% 4% 7% 8% 10% 10% 10% 10% 11% 12% 11% 12%
3 2 6 3 3 2 7 2 4 4 3 2 4
Interest 0 0 1 0 1 1 1 1 1 1 1 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 7 6 6 5 5 6 10 6 8 9 9 10 15
Tax % 23% 33% 16% 22% 33% 30% 18% 27% 24% 25% 27% 24% 25%
6 4 5 4 4 4 8 4 6 6 7 8 11
EPS in Rs 0.07 0.05 0.06 0.04 0.04 0.04 0.09 0.05 0.07 0.07 0.07 0.08 0.12
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
115 151 173 184 185 159 187 206 245 216 222 257 324
104 135 155 167 168 147 175 189 207 196 202 229 287
Operating Profit 11 16 18 17 16 12 12 17 38 20 20 28 37
OPM % 9% 11% 11% 9% 9% 7% 6% 8% 16% 9% 9% 11% 11%
1 1 1 3 3 4 5 5 7 12 15 13 14
Interest 1 0 0 0 0 0 0 1 0 2 3 5 3
Depreciation 3 3 3 3 3 4 4 4 4 4 5 5 5
Profit before tax 8 14 16 16 16 12 13 17 41 26 27 32 43
Tax % 33% 33% 38% 36% 33% 28% 12% 18% 28% 24% 24% 26%
6 9 10 10 11 9 11 14 29 20 20 24 32
EPS in Rs 0.07 0.12 0.13 0.13 0.14 0.11 0.14 0.18 0.37 0.23 0.21 0.25 0.34
Dividend Payout % 24% 17% 16% 15% 15% 0% 0% 0% 0% 13% 0% 0%
Compounded Sales Growth
10 Years: 5%
5 Years: 7%
3 Years: 2%
TTM: 35%
Compounded Profit Growth
10 Years: 9%
5 Years: 16%
3 Years: -7%
TTM: 38%
Stock Price CAGR
10 Years: 11%
5 Years: 91%
3 Years: 1%
1 Year: 17%
Return on Equity
10 Years: 10%
5 Years: 10%
3 Years: 9%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 22 78 78 78 78 78 78 78 79 86 94 94 94
Reserves 65 17 22 31 36 44 55 68 109 136 162 192 218
2 3 6 6 12 12 9 2 62 58 83 72 14
33 42 31 61 48 37 32 33 42 28 38 33 44
Total Liabilities 123 140 138 175 175 171 173 181 292 308 377 392 369
50 50 46 46 85 89 89 93 91 94 91 120 117
CWIP 0 0 0 5 0 1 0 0 0 6 26 0 1
Investments 7 9 6 23 1 2 2 1 11 43 64 66 86
66 80 85 101 89 79 83 87 189 165 196 206 165
Total Assets 123 140 138 175 175 171 173 181 292 308 377 392 369

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
6 0 0 24 17 -2 4 6 -2 16 10 -6
-0 0 1 -23 -8 -2 2 2 -75 -27 -45 84
-6 0 1 -2 -2 -2 -0 -7 72 8 35 -15
Net Cash Flow -1 0 2 -1 6 -6 7 1 -5 -2 1 63

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 92 71 66 91 91 87 81 77 112 114 124 132
Inventory Days 29 36 34 43 29 37 37 39 51 51 53 49
Days Payable 91 105 63 130 92 75 57 49 66 36 52 33
Cash Conversion Cycle 29 1 37 4 27 49 61 67 96 129 124 148
Working Capital Days 101 83 97 51 70 103 90 92 121 131 133 153
ROCE % 10% 15% 16% 15% 14% 9% 9% 12% 21% 11% 10% 10%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
44.01% 46.12% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% 0.09% 0.10%
55.99% 53.88% 49.43% 49.43% 49.43% 49.44% 49.44% 49.44% 49.44% 49.35% 49.34% 49.34%
No. of Shareholders 1,88,9812,32,6172,35,5172,32,7502,32,0692,27,4782,24,9252,24,2522,89,9823,25,7613,76,5304,69,242

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue